VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Wasim Aluísio Prates-Syed, Lorena C. S. Chaves, Karin P. Crema, Larissa Vuitika, Aline Lira, Nelson Côrtes, Victor Kersten, Francisco Eduardo Gontijo Guimarães, Mohammad Sadraeian, Fernando Luís Barroso da Silva, Otávio Cabral-Marques, José Alexandre Marzagão Barbuto, Momtchilo Russo, Niels Olsen Saraiva Câmara, Gustavo Cabral‐Miranda
Abstract
Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.